INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• INmune Bio, Inc. has received a consensus recommendation of "Moderate Buy" from seven research firms, with one sell rating and three buy ratings.
• The average twelve-month target price for INmune Bio among analysts is $18.40, while the stock opened at $2.01.
• Significant institutional investments have been noted, with JPMorgan Chase & Co. increasing its stake by 1,042.7% in the second quarter.

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) has earned an average rating of "Moderate Buy" from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $18.40.

A number of research firms recently commented on INMB. Raymond James Financial cut shares of INmune Bio from a "moderate buy" rating to a "hold" rating in a research note on Monday, June 30th. Wall Street Zen cut shares of INmune Bio from a "hold" rating to a "sell" rating in a report on Saturday, August 2nd. Maxim Group lowered their price objective on INmune Bio from $30.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, July 2nd. Scotiabank restated a "sector underperform" rating on shares of INmune Bio in a report on Tuesday, July 1st. Finally, BTIG Research reissued a "neutral" rating on shares of INmune Bio in a report on Tuesday, July 1st.

INmune Bio Stock Performance

Shares of INmune Bio stock traded down $0.03 during midday trading on Friday, reaching $1.95. 135,667 shares of the company's stock traded hands, compared to its average volume of 1,470,000. INmune Bio has a 12 month low of $1.71 and a 12 month high of $11.64. The company has a market cap of $51.71 million, a PE ratio of -0.78 and a beta of 1.03. The stock has a 50 day moving average of $2.33 and a 200-day moving average of $5.43.

INmune Bio (NASDAQ:INMB - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. On average, equities analysts anticipate that INmune Bio will post -2.24 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Dimensional Fund Advisors LP lifted its position in INmune Bio by 71.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 25,139 shares of the company's stock worth $117,000 after purchasing an additional 10,491 shares during the period. Northern Trust Corp grew its position in INmune Bio by 9.5% in the 4th quarter. Northern Trust Corp now owns 105,961 shares of the company's stock valued at $495,000 after purchasing an additional 9,154 shares during the period. BNP Paribas Financial Markets grew its position in INmune Bio by 799.9% in the 4th quarter. BNP Paribas Financial Markets now owns 25,513 shares of the company's stock valued at $119,000 after purchasing an additional 22,678 shares during the period. Bank of America Corp DE boosted its position in INmune Bio by 15.2% in the fourth quarter. Bank of America Corp DE now owns 30,449 shares of the company's stock worth $142,000 after purchasing an additional 4,015 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in INmune Bio by 43.9% in the 4th quarter. Millennium Management LLC now owns 291,327 shares of the company's stock worth $1,360,000 after buying an additional 88,823 shares during the period. Institutional investors own 12.72% of the company's stock.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.